We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Oncobiologics, Inc. (delisted) | NASDAQ:ONS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.646 | 0.61 | 0.70 | 0 | 01:00:00 |
|
Delaware
|
| |
2836
|
| |
38-3982704
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(Primary Standard Industrial
Classification Code Number) |
| |
(I.R.S. Employer
Identification Number) |
|
|
Large accelerated filer ☐
|
| |
Accelerated filer ☐
|
| |
Non-accelerated filer ☐
|
| |
Smaller reporting company ☒
|
|
| | | | | | |
(Do not check if a smaller reporting company)
|
| |
Emerging growth company ☒
|
|
TABLE OF CONTENTS
|
| |
Page
|
||
| | | | 1 | |
| | | | 2 | |
| | | | 5 | |
| | | | 6 | |
| | | | 7 | |
| | | | 8 | |
| | | | 12 | |
| | | | 13 | |
| | | | 14 | |
| | | | 15 | |
| | | | 16 | |
| | | | 18 | |
| | | | 23 | |
| | | | 23 | |
| | | | 23 | |
| | | | 23 |
|
Assumed Average
Purchase Price Per Share |
| |
Number of Registered
Shares to be Issued if Full Purchase (1)(2) |
| |
Percentage of Outstanding
Shares After Giving Effect to the Issuance to Lincoln Park (3) |
| |
Gross Proceeds from the Sale of
Registered Shares to Lincoln Park Under the Purchase Agreement |
| |||||||||
|
$1.50
(4)
|
| | | | 4,737,960 | | | | | | 16.5 % | | | | | $ | 7,106,940 | | |
|
$2.73
(5)
|
| | | | 4,737,960 | | | | | | 16.5 % | | | | | $ | 12,934,631 | | |
|
$3.00
|
| | | | 4,737,960 | | | | | | 16.5 % | | | | | $ | 14,213,880 | | |
|
$4.00
|
| | | | 3,750,000 | | | | | | 13.6 % | | | | | $ | 15,000,000 | | |
|
$5.00
|
| | | | 3,000,000 | | | | | | 11.1 % | | | | | $ | 15,000,000 | | |
| | |
Common Stock
|
| |||||||||
| | |
High
|
| |
Low
|
| ||||||
Fiscal Year 2018 Year-to-Date | | | | ||||||||||
Second quarter (through February 13, 2018)
|
| | | $ | 1.26 | | | | | $ | 1.14 | | |
First quarter
|
| | | | 1.44 | | | | | | 1.14 | | |
Fiscal Year 2017 | | | | ||||||||||
Fourth quarter
|
| | | | 2.02 | | | | | | 0.83 | | |
Third quarter
|
| | | | 2.53 | | | | | | 0.98 | | |
Second quarter
|
| | | | 3.75 | | | | | | 2.65 | | |
First quarter
|
| | | | 4.33 | | | | | | 1.89 | | |
Fiscal Year Ended September 30, 2016 | | | | ||||||||||
Fourth quarter
|
| | | | 5.49 | | | | | | 3.04 | | |
Third quarter (from June 13, 2016)
|
| | | | 4.48 | | | | | | 3.25 | | |
Selling Stockholder
|
| |
Shares
Beneficially Owned Before this Offering |
| |
Percentage
of Outstanding Shares Beneficially Owned Before this Offering |
| |
Shares to be
Sold in this Offering Assuming We Issue the Maximum Number of Shares Under the Purchase Agreement |
| |
Percentage
of Outstanding Shares Beneficially Owned After this Offering |
| ||||||||||||
Lincoln Park Capital Fund, LLC
(1)
|
| | | | 263,581 (2 ) | | | | | | 1.0 % (3) | | | | | | 5,114,747 (4 ) | | | | | | * | | |
Item
|
| |
Amount to
be paid |
| |||
SEC filing fee
|
| | | $ | 1,607 | | |
Legal fees and expenses
|
| | | | 75,000 | | |
Accounting fees and expenses
|
| | | | 12,500 | | |
Printing and miscellaneous expenses
|
| | | | 25,893 | | |
Total
|
| | | $ | 115,000 | | |
|
Exhibit
Number |
| |
Description
|
|
10.51 | | | Amendment #2 to the Warrant Agreement dated May 18, 2016 by and between Oncobiologics, Inc. and American Stock Transfer & Trust Company, LLC, as Warrant Agent, dated February 9, 2018 (incorporated by reference to Exhibit 10.1 the Registrant's current report on Form 8-K filed with the SEC on February 9, 2018). | |
23.1 | | | Consent of independent registered public accounting firm. | |
23.2 | | | Consent of Cooley LLP (included in Exhibit 5.1). | |
24.1 | | | Power of Attorney (included on signature page). | |
101.INS | | | XBRL Instance Document (incorporated by reference to Exhibit 101.INS to the Registrant’s Annual Report on Form 10-K for the year ended September 30, 2017, filed with the SEC on December 29, 2017). | |
101.SCH | | | XBRL Taxonomy Extension Schema Document (incorporated by reference to Exhibit 101.SCH to the Registrant’s Annual Report on Form 10-K for the year ended September 30, 2017, filed with the SEC on December 29, 2017). | |
101.CAL | | | XBRL Taxonomy Extension Calculation Linkbase Document (incorporated by reference to Exhibit 101.CAL to the Registrant’s Annual Report on Form 10-K for the year ended September 30, 2017, filed with the SEC on December 29, 2017). | |
101.DEF | | | XBRL Definition Linkbase Document (incorporated by reference to Exhibit 101.DEF to the Registrant’s Annual Report on Form 10-K for the year ended September 30, 2017, filed with the SEC on December 29, 2017). | |
101.LAB | | | XBRL Taxonomy Extension Labels Linkbase Document (incorporated by reference to Exhibit 101.LAB to the Registrant’s Annual Report on Form 10-K for the year ended September 30, 2017, filed with the SEC on December 29, 2017). | |
101.PRE | | | XBRL Taxonomy Extension Presentation Linkbase Document (incorporated by reference to Exhibit 101.PRE to the Registrant’s Annual Report on Form 10-K for the year ended September 30, 2017, filed with the SEC on December 29, 2017). | |
| | | | ONCOBIOLOGICS, INC. | | |||
| | | | By: | | | /s/ Pankaj Mohan | |
| | | | | | | Pankaj Mohan, Ph.D. | |
| | | | | | | Chairman, President and Chief Executive Officer | |
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Pankaj Mohan
Pankaj Mohan, Ph.D.
|
| |
Chairman, President and Chief Executive Officer
(Principal Executive Officer) |
| |
February 15, 2018
|
|
|
/s/ Lawrence A. Kenyon
Lawrence A. Kenyon
|
| |
Chief Financial Officer
(Principal Accounting and Financial Officer) |
| |
February 15, 2018
|
|
|
/s/ Claudio Albrecht
Claudio Albrecht, M.D., Ph.D.
|
| |
Director
|
| |
February 15, 2018
|
|
|
/s/ Scott A. Canute
Scott A. Canute
|
| |
Director
|
| |
February 15, 2018
|
|
|
/s/ Yezan M. Haddadin
Yezan M. Haddadin
|
| |
Director
|
| |
February 15, 2018
|
|
|
/s/ Kurt J. Hilzinger
Kurt J. Hilzinger
|
| |
Director
|
| |
February 15, 2018
|
|
|
/s/ Faisal G. Sukhtian
Faisal G. Sukhtian
|
| |
Director
|
| |
February 15, 2018
|
|
|
/s/ Joe Thomas
Joe Thomas
|
| |
Director
|
| |
February 15, 2018
|
|
1 Year ONCOBIOLOGICS, INC. Chart |
1 Month ONCOBIOLOGICS, INC. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions